Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Medi-Tate Ltd., Announces the Enrollment of the First Fifty Patients in its Second Multi-center European Study on iTind

Medi-Tate Ltd.
Posted on: 24 Jul 18
Medi-Tate Ltd., Announces the Enrollment of the First Fifty Patients in its Second Multi-center European Study on iTind

PR Newswire

OR AKIVA, Israel, July 24, 2018

OR AKIVA, Israel, July 24, 2018 /PRNewswire/ --

Medi-Tate Ltd., a medical device company focused on addressing unmet needs in the field of urology, today announced the enrollment of the first fifty patients in its second multi-center European study on the iTind, a novel, minimally invasive treatment for the relief of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), or enlarged prostate.

This new study is being carried out across ten sites in Italy, Germany, Spain and Greece, and will include a total of 200 patients. The study is designed to demonstrate the safety and effectiveness of the iTind® System in patients of all ages, and with prostate volumes of up to 120ml.

"Most men suffering from BPH have a prostate volume of under 75ml, and would be suitable candidates for iTind based on our clinical data and experience to date," said Ido Kilemnik, CEO, Medi-Tate. "However, about 20% of BPH patients have prostates with a volume greater than 75ml. This new clinical study will allow us to understand the upper prostate volume that can be effectively treated with iTind so that an even greater number of men can benefit from this exciting technology."

About the iTind System

The CE Marked iTind System is a minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) without heating or resecting tissue, and without leaving behind a permanent implant. The iTind, temporarily implanted nitinol cutting device, is implanted through a straightforward, minimally invasive transurethral procedure and left in place for only 5 to 7 days. While in-situ, the iTind device expands, exerting radial force on the tissue and creating ischemic incisions in the prostatic urethra and bladder neck to relieve the obstruction. After only 5 to 7 days, the procedure is complete and the device is completely removed. The iTind System is available in the Europe, Canada, and Hong Kong. Learn more at www.itind.com.

About Medi-Tate

Medi-Tate is an Israeli medical device company that deals in the R&D, manufacture and sale of innovative solutions for the treatment of Lower Urinary Tract Symptoms (LUTS) with a mission to commercialize a safe and effective, office-based solution for BPH.
Learn more at www.itind.com.

Media Contact:
Vanessa Malka
VP Business Development and Marketing
vanessa@medi-tate.com


SOURCE Medi-Tate Ltd.

PR Newswire
www.prnewswire.com

Last updated on: 24/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.